Evidence map›Paper›PMID 32496149›Full record

ArticleJournal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology2021

Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.

Lindsey M Charo, Michael V Homer, Loki Natarajan, Carolyn Haunschild, Karine Chung, Jun J Mao, Angela M DeMichele, H Irene Su

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Alkannin Inhibits the Development of Ovarian Cancer by Affecting miR-4461.Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Lindsey M CharoDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, CA, USA.ORCID https://orcid.org/0000-0002-4271-7195
Michael V HomerDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, CA, USA.
Loki NatarajanMoores Cancer Center, University of California, San Diego, CA, USA.
Carolyn HaunschildDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, CA, USA.
Karine ChungDepartment of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
Jun J MaoIntegrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Angela M DeMicheleDepartment of Internal Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
H Irene SuDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, CA, USA.
University of California San Diego · USMemorial Sloan Kettering Cancer Center · USUniversity of Pennsylvania · USUniversity of Southern California · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
The Reproductive Window in Young Adult Cancer SurvivorsR01HD080952 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SU, HUI-CHUN IRENE · 2014 to 2018
$2.6M
NCI NIH HHS P30 CA008748NICHD NIH HHS R01 HD080952
6 · The paper itself

Abstract

Cyclophosphamide is associated with chemotherapy-related ovarian failure (CROF) in breast cancer survivors, however little is known about predicting individual risks. We sought to identify genetic alleles as biomarkers for risk of CROF after cyclophosphamide treatment. One hundred fifteen premenopausal women with newly diagnosed breast cancer were genotyped for single nucleotide polymorphisms (SNPs) in genes involved in cyclophosphamide activation (

Indexed as

AdultAllelesAntineoplastic Agents, AlkylatingBreast NeoplasmsCancer SurvivorsCyclophosphamideCytochrome P-450 CYP2C19Cytochrome P-450 CYP3AFemaleGenotypeGlutathione S-Transferase piGlutathione TransferaseHumansLongitudinal StudiesPharmacogenomic VariantsPolymorphism, Single NucleotideAntineoplastic Agents, AlkylatingCyclophosphamideCYP2C19 protein, humanCYP3A4 protein, humanCytochrome P-450 CYP2C19Cytochrome P-450 CYP3AGlutathione S-Transferase piGlutathione TransferaseGSTA1 protein, humanGSTP1 protein, humanBreast cancerCYP2C19CYP3A4; GSTP1GSTA1ovarian failure

Identifiers

PMID32496149
PMCPMC9647890
OpenAlexW3030327235

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.